VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Completed · Phase 4 · Has a placebo group

Conditions studied: Postmenopausal Osteoporosis

In brief

The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.

Key facts

Study ID
NCT01709110
Run by
Eli Lilly and Company
People needed
1366
Starts
2012-10-01
Expected to finish
2016-07-01
Last updated by the study team
2019-09-23

Who can join

Age: 45 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.